Advertisement

Search Results

Advertisement



Your search for The ASCO Post Staff matches 2774 pages

Showing 151 - 200


kidney cancer
immunotherapy

No Survival Difference for Front-Line Combination Regimens in Intermediate- and Poor-Risk Clear Cell RCC: Real-World Outcomes

A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they were treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab. These...

pain management
issues in oncology

Results of a Restrictive Opioid Prescription Protocol for Patients With Cancer Undergoing Surgery

Seeing an opportunity to safely reduce the number of opioid doses prescribed to patients with cancer, researchers proposed a new pain management guideline for all patients undergoing surgery at Roswell Park Comprehensive Cancer Center. The results from the first 6 months of that effort, reported by ...

skin cancer
immunotherapy

High-Dose Interferon or Ipilimumab vs Pembrolizumab for High-Risk Resected Melanoma

Patients with high-risk melanoma who had a course of pembrolizumab had longer recurrence-free survival than patients who received either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, were presented by Grossmann et al...

breast cancer

Efficacy of Platinum Chemotherapy vs Capecitabine for Basal-Like Triple-Negative Breast Cancer

About 80% of triple-negative breast cancers are classified as the subtype basal-like. Typically, patients with triple-negative breast cancer receive chemotherapy before surgery. The presence of residual cancer in the breast after chemotherapy signals a higher likelihood that the cancer will...

covid-19

Remote Monitoring Program Reduced Hospitalization Among Patients With Cancer Infected With COVID-19

A study by researchers at Mayo Clinic Cancer Center found that patients with cancer diagnosed with COVID-19 who received care at home via remote patient monitoring were significantly less likely to require hospitalization for their illness, compared to patients with cancer infected with the virus...

skin cancer
immunotherapy

Extended Follow-up of Nivolumab/Ipilimumab for Metastatic Melanoma

In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive at a median of 6.5 years after treatment. These long-term results from the...

gynecologic cancers
pancreatic cancer

Electronic Olfaction System Under Study as Screening Tool for Pancreatic and Ovarian Cancers

An odor-based test that detects vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy, according to a new study presented by Johnson et al during the 2021 ASCO Annual Meeting (Abstract 5544). The findings suggest...

lung cancer
genomics/genetics

Sotorasib for KRAS G12C–Mutated NSCLC: Overall Survival and Exploratory Subgroup Analyses

Results from the phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and a median overall survival of 12.5 months in previously treated patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC)....

breast cancer
covid-19

Study Examines Relationship Between Risk of COVID-19 Infection and Breast Cancer Treatment

In a study led by researchers at NYU Langone Health and its Perlmutter Cancer Center involving more than 3,000 women treated for breast cancer at the height of the COVID-19 pandemic in New York City, only 64 patients, or 2% of the total study population, contracted the virus. Of this group, 10 died ...

head and neck cancer

Transoral Surgery Followed by Lower-Dose Radiation in Patients With HPV-Associated Oropharyngeal Cancer at Intermediate Risk of Recurrence

The phase II E3311 trial offers new information about using reduced-intensity treatment in patients with human papillomavirus (HPV)-associated oropharyngeal cancer who are at intermediate risk of recurrence. These findings were presented by Robert L. Ferris, MD, PhD, and colleagues during the 2021...

lung cancer
immunotherapy

Byoung Chul Cho, MD, PhD, on NSCLC: Amivantamab Plus Lazertinib for Treatment of Relapsed Disease

Byoung Chul Cho, MD, PhD, of the Yonsei Cancer Center, discusses study results that showed treatment with the EGFR-MET bispecific antibody amivantamab plus the EGFR inhibitor lazertinib yielded responses in 36% of chemotherapy-naive patients with non–small cell lung cancer whose disease progressed...

lung cancer
genomics/genetics
immunotherapy

Pasi A. Janne, MD, PhD, on NSCLC: Patritumab Deruxtecan to Target HER3

Pasi A. Janne, MD, PhD, of Dana-Farber Cancer Institute, discusses study findings that show patritumab deruxtecan is effective in patients with EGFR-mutated and inhibitor-resistant non–small cell lung cancer. Dr. Janne also explains why targeting HER3, a mutation expressed in most EGFR-altered...

multiple myeloma

Taiga Nishihori, MD, on Multiple Myeloma: Maintenance Ixazomib After Transplant

Taiga Nishihori, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the outcome of a trial that explored maintenance therapy with ixazomib after allogeneic hematopoietic cell transplantation in patients with high-risk multiple myeloma. Toxicities unrelated to the maintenance...

lung cancer
issues in oncology

Debora S. Bruno, MD, on NSCLC: Racial Disparities in Biomarker Testing and Clinical Trial Enrollment

Debora S. Bruno, MD, of Seidman Cancer Center at Cleveland Medical Center, discusses study findings that show Black patients with advanced or metastatic non–small cell lung cancer tend to be less likely to undergo biomarker testing or to be treated in clinical trials than White patients....

gynecologic cancers

Linda R. Mileshkin, MBBS, MD, on Cervical Cancer: Adjuvant Chemotherapy After Chemoradiation

Linda R. Mileshkin, MBBS, MD, of the Peter MacCallum Cancer Centre, discusses phase III findings from the OUTBACK trial, which showed that adjuvant chemotherapy given after standard cisplatin-based chemoradiation for women with locally advanced cervical cancer did not improve either overall or...

prostate cancer

Michael J. Morris, MD, on Prostate Cancer: LuPSMA in the Metastatic Setting

Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the VISION study, which showed that lutetium-177–PSMA-617 (LuPSMA), a targeted radioligand therapy, plus standard-of-care treatment improves radiographic progression-free survival and extends overall...

gastroesophageal cancer
immunotherapy

Ian Chau, MD, on Esophageal Squamous Cell Carcinoma: Nivolumab, Ipilimumab, and Chemotherapy for Advanced Disease

Ian Chau, MD, of Royal Marsden NHS Foundation Trust, discusses first results of the CheckMate 648 study, which showed that nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated superior overall survival vs chemotherapy alone in patients with advanced esophageal squamous cell...

kidney cancer
immunotherapy

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Pembrolizumab vs Placebo in Adjuvant Treatment

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results from KEYNOTE-564, which evaluated the safety and efficacy of pembrolizumab in the adjuvant treatment of patients with renal cell carcinoma who have undergone nephrectomy for intermediate-high or high-risk disease or...

breast cancer
genomics/genetics

Andrew Tutt, PhD, MBChB, on Breast Cancer: Olaparib After Chemotherapy in Germline BRCA1/2–Mutated Tumors

Andrew Tutt, PhD, MBChB, of the Institute of Cancer Research, London, discusses findings from the phase III OlympiA trial, which showed that adjuvant olaparib, a PARP inhibitor, following adjuvant or neoadjuvant chemotherapy, may improve invasive disease–free survival in patients with germline...

leukemia
immunotherapy

Ponatinib/Blinatumomab Demonstrates High Rates of Complete Molecular Response in Philadelphia Chromosome–Positive ALL

The combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). The study—presented by Nicholas J. Short, MD, and colleagues during the 2021 ASCO...

issues in oncology

Community-Based Engagement Initiative Improves Accrual of Black Participants in Clinical Trials

A 5-year community outreach and engagement effort by the Abramson Cancer Center at the University of Pennsylvania to increase enrollment of Black patients into cancer clinical trials more than doubled the percentage of participants, improving access and treatment for a group of patients with...

breast cancer
symptom management
pain management

Study Examines Aromatase Inhibitor–Associated Musculoskeletal Symptoms in a Diverse Population With Early Breast Cancer

A clinical trial in a racially diverse group of postmenopausal women with early breast cancer to study severe pain in the bones, muscles, ligaments, tendons, and nerves caused by aromatase inhibitor treatment has found that the symptoms were more commonly reported in Black and Asian patients than...

solid tumors
genomics/genetics
immunotherapy

Pertuzumab/Trastuzumab Demonstrates Activity in Tissue-Agnostic Trial for Patients With HER2-Positive Tumors

Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with KRAS mutations....

ASCO Board of Directors and Nominating Committee

ASCO has elected five new members to the ASCO Board of Directors and the Nominating Committee for 4- and 3-year terms, respectively, starting in June 2021: Gladys I. Rodriguez, MD, has been elected to a Designated Community Oncologist seat on the Board. Dr. Rodriguez is Vice President of...

New FDA-Approved Oncology Drugs and Label Updates Between May 8, 2020, and May 8, 2021

Over the past year (May 2020–May 2021), the U.S. Food and Drug Administration (FDA) approved and expanded indications for many drugs related to the treatment of different types of cancers and adverse events. The new approvals and accelerated approvals are listed below. PEMBROLIZUMAB (KEYTRUDA) in...

Narratives in Oncology Through the Years

Beginning in 2012,The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past years, many in the oncology community have been profiled in this commemorative issue. A complete list of individuals...

Eric P. Winer, MD, FASCO, Elected ASCO President for 2022–2023 Term

ASCO has elected Eric P. Winer, MD, FASCO, to serve as its President for the term beginning in June 2022. He will take office as President-Elect during the ASCO Annual Meeting in June 2021. “ASCO is as equally devoted to improving outcomes for patients as it is to supporting oncology professionals ...

issues in oncology
covid-19

Organizations Issue Statement Encouraging Return to HPV Vaccination

Doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations recently issued a joint statement urging the nation’s health-care systems, physicians, parents, children, and young adults to get human papillomavirus (HPV) vaccination back on ...

survivorship

Study Examines Barriers to Survivorship Care

Even among a large group of cancer survivors who were mostly insured, college-educated, and had annual incomes above the national average, up to 10% delayed care in the previous 12 months because they simply could not afford out-of-pocket expenses like copays and deductibles. These findings were...

hepatobiliary cancer
genomics/genetics

FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma With an FGFR2 Fusion or Rearrangement

On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the kinase inhibitor infigratinib (Truseltiq) for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or ...

lung cancer
genomics/genetics

FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC

On May 28, the U.S. Food and Drug Administration (FDA) approved sotorasib (Lumakras) as the first treatment for adult patients with non–small cell lung cancer (NSCLC) whose tumors have a KRAS G12C genetic mutation and who have received at least one prior systemic therapy. This is the first approved ...

skin cancer
immunotherapy

Evan J. Lipson, MD, on Melanoma: Relatlimab and Nivolumab in First-Line Treatment of Advanced Disease

Evan J. Lipson, MD, of Johns Hopkins University, discusses primary phase III results from the RELATIVITY-047 study, which showed that relatlimab plus nivolumab as a fixed-dose combination may improve progression-free survival compared with nivolumab monotherapy in patients with advanced melanoma....

prostate cancer

FDA Approves Piflufolastat F-18 Injection, a PSMA PET Imaging Agent, for the Detection of Metastatic or Recurrent Prostate Cancer

On May 27, the U.S. Food and Drug Administration (FDA) approved piflufolastat F-18 injection (Pylarify), an F-18–labeled prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) imaging agent, to identify suspected metastasis or recurrence of prostate cancer. This is...

issues in oncology

School-Based HPV Vaccination Program Reduces Rates of HPV in Gay and Bisexual Men

An Australian study published by Chow et al in The Lancet Infectious Diseases found a 70% reduction in one type of human papillomavirus (HPV) in gay and bisexual men after the implementation of the school-based HPV vaccination program. The HYPER2 study found that there was a significant reduction...

kidney cancer

AUA Announces Updates to Clinical Guidance for Renal Mass and Localized Renal Cancer

The American Urological Association (AUA) announced amendments to its clinical guideline on Renal Masses and Localized Renal Cancer, originally published in 2013 and updated in 2017, based on an additional literature search conducted through October 2020. One in four renal masses are benign;...

lung cancer
immunotherapy

ORIENT-12 Study: Addition of Sintilimab to Gemcitabine/Platinum in Advanced Squamous NSCLC

Adding sintilimab to a regimen of gemcitabine and platinum demonstrated clinical benefit over gemcitabine and platinum alone as first-line therapy in patients with locally advanced or metastatic squamous non–small cell lung cancer (NSCLC). These results from the ORIENT-12 trial were published by...

issues in oncology
covid-19

Association of Community Cancer Centers Releases Report: Trending Now in Cancer Care 2020

The Association of Community Cancer Centers (ACCC) released Trending Now in Cancer Care 2020, an annual report that identifies current and emerging trends in cancer programs across the country. The detailed report presents findings from focus groups that illuminate the short- and long-term impact...

Lustgarten Foundation–AACR Career Development Awards for Pancreatic Cancer Research

Dannielle Engle, PhD, of the Salk Institute for Biological Studies, and Avery D. Posey, PhD, of the Perelman School of Medicine at the University of Pennsylvania, were announced at the American Association for Cancer Research (AACR) Annual Meeting 2021 as the inaugural recipients of the Lustgarten...

Agnes Witkiewicz, MD, to Lead Roswell Park’s Cancer Genetics and Genomics Department

Roswell Park Comprehensive Cancer Center has appointed Agnes ­Witkiewicz, MD, as Director of Cancer Genetics and Genomics. She will also hold the John & Santa Palisano Endowed Chair of Cancer Genetics. An internationally recognized clinician-scientist who combines groundbreaking laboratory...

American Academy of HIV Medicine Names Leslie McGorman, MPPA, as Director of Public Policy

The American Academy of Human Immunodeficiency Virus (HIV) Medicine recently announced the appointment of Leslie McGorman, MPPA, as its new Director of Public Policy. A seasoned professional in both federal and state government affairs, Ms. McGorman possesses 20 years of health policy experience...

AUA Names 2021 Award Recipients

Each year, the American Urological Association (AUA) honors the contributions of physician researchers and educators in the field of medicine, the specialty of urology, and the organization. The following individuals are the 2021 honorees: Ian M. Thompson Jr, MD, Ramon Guiteras Award, for...

Sloan Kettering Institute Researchers Awarded 2021 Kravis Women in Science Endeavor Fellowship Grants

Memorial Sloan kettering Cancer Center (MSK) announced that Sloan Kettering Institute (SKI) researchers Regina Bou Puerto and Mijin Kim, PhD, have been named 2021 Marie-Josée Kravis Women in Science Endeavor (Kravis WiSE) fellowship grant recipients. The Kravis WiSE initiative, created in 2020,...

St. Jude Children’s Research Hospital Announces Its Largest Strategic Expansion

St. Jude Children’s Research Hospital is launching the biggest strategic investment in its nearly 60-year history, committing $11.5 billion during the next 6 years to accelerate research and treatment globally for children with catastrophic diseases. The Six-Year St. Jude Strategic Plan focuses on...

Roswell Park, Wilmot Cancer Institute Collaborate in Study of Immunotherapy for Black Patients With Cancer

A NEW COLLABORATION between two Western New York cancer research leaders will help oncologists learn whether Black and White patients with cancer respond differently to immunotherapy and seek to improve the safety and effectiveness of these newer drugs in diverse populations. Funded by a 2-year,...

Nima Sharifi, MD, Receives 2021 AACR–Waun Ki Hong Award in Translational and Clinical Cancer Research

THE AMERICAN ASSOCIATION for Cancer Research (AACR) has recognized Nima Sharifi, MD, with the 2021 AACR–Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. Dr. Sharifi is Director of the Center for Genitourinary Malignancies Research at Lerner Research...

Ton Schumacher, PhD, FAACR, Receives 2021 AACR-CRI Lloyd J. Old Award in Cancer Immunology

THE AMERICAN ASSOCIATION for Cancer Research (AACR) recognized Ton Schumacher, PhD, FAACR, with the 2021 AACR-CRI Lloyd J. Old Award in Cancer Immunology during the virtual AACR Annual Meeting 2021 in April. The award recognizes an active scientist whose outstanding and innovative research has made ...

Stand Up To Cancer Funds $6 Million for Disparities in Cancer Clinical Trials Research

STAND UP TO CANCER® (SU2C) has awarded $6 million to a multi-institutional team headed by Mount Sinai researchers to collaborate with other New York institutions in an initiative that addresses disparities in cancer clinical trials participation by patients who are Black, indigenous, and people of...

issues in oncology

Narjust Duma, MD, and Gladys I. Rodriguez, MD, on A First for Hispanic Women: Formation of a YIA for Latinas

Narjust Duma, MD, of the Carbone Cancer Center at the University of Wisconsin, Madison, and Gladys I. Rodriguez, MD, of South Texas Oncology and Hematology, talk about the underrepresentation of Hispanic individuals in medicine, especially in oncology, and their efforts to create the first Young...

breast cancer
covid-19

Inequities in Breast Cancer Screening During the COVID-19 Pandemic

Breast cancer screening took a sizeable hit during the COVID-19 pandemic, according to new research  showing that the number of screening mammograms completed in a large group of women living in Washington state plummeted by nearly half. Published by Amram et al in JAMA Network Open, the study...

hepatobiliary cancer

Does Long-Term Suppression of Hepatitis B in Patients With HIV Lower Risk of Hepatocellular Carcinoma?

While the risk of hepatocellular carcinoma (HCC) is higher among patients who have human immunodeficiency virus (HIV), it’s even higher among patients who have HIV and detectable hepatitis B, according to research published by Kim et al in Hepatology. Among patients with HIV and hepatitis B,...

Advertisement

Advertisement



Advertisement